Head to Head Survey: Alpha Tau Medical (NASDAQ:DRTS) & Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Volatility and Risk

Femasys has a beta of -2.52, indicating that its stock price is 352% less volatile than the S&P 500. Comparatively, Alpha Tau Medical has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Femasys and Alpha Tau Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-1,435.77%	-141.49%	-82.30%
Alpha Tau Medical	N/A	-38.62%	-29.89%

Earnings and Valuation

This table compares Femasys and Alpha Tau Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.63 million	19.06	-$14.25 million	($0.85)	-1.34
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.45)	-5.76

Femasys has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 2.7% of Alpha Tau Medical shares are owned by institutional investors. 12.3% of Femasys shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Femasys and Alpha Tau Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	0	0	2	0	3.00
Alpha Tau Medical	0	0	2	0	3.00

Femasys currently has a consensus price target of $11.50, suggesting a potential upside of 908.77%. Alpha Tau Medical has a consensus price target of $8.00, suggesting a potential upside of 208.88%. Given Femasys’ higher probable upside, research analysts clearly believe Femasys is more favorable than Alpha Tau Medical.

Summary

Alpha Tau Medical beats Femasys on 6 of the 11 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.